Evidence map›Paper›PMID 40855380›Full record

ArticleAAPS PharmSciTech2025

Tabletability Enhancement of Acetaminophen Coated with a Nanocellulose Suspension using a Fluidized Bed.

Zhixing Lin, Maxx Capece

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhixing LinDrug Product Development, Research and Development, Abbvie Inc, 1 N. Waukegan Road, North Chicago, Illinois, 60064, USA.
Maxx CapeceDrug Product Development, Research and Development, Abbvie Inc, 1 N. Waukegan Road, North Chicago, Illinois, 60064, USA. maxx.capece@abbvie.com.ORCID http://orcid.org/0009-0003-9760-2082

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fluidized bed coating was investigated as a method to coat aqueous suspensions of nanocellulose onto acetaminophen (APAP) for the purpose of tabletability enhancement. Effects of suspension concentration and fluidized bed processing conditions were evaluated. Nanocellulose coatings of up to 2.0% w/w were achieved. This study found that the nanocellulose coating significantly improved the tabletability of APAP. A 2.0% w/w coating increased tablet tensile strength by nearly 200%. With respect to tablet formulation, it was found that APAP coated with 2.0% w/w nanocellulose allowed a 60% reduction in filler to produce tablets acceptable for manufacturing compared to APAP without nanocellulose. The effectiveness of fluidized bed coating was also compared to a twin-screw extrusion process which was previously used to coat nanocellulose onto APAP. It was concluded that process conditions and the process method had no effect on the extent of tabletability enhancement provided by nanocellulose. Improvement to tabletability was only dependent on the concentration of nanocellulose coated. Fluidized bed coating may be more advantageous than twin-screw processing due to the inherent ability of the former to better control liquid addition and removal. Accordingly, fluidized bed coating was able to achieve a higher coating concentration than the twin-screw process. Overall, the use of small amounts of nanocellulose to substantially improve tabletability of APAP and to reduce the need for filler excipients is evident.

Indexed as

AcetaminophenCelluloseChemistry, PharmaceuticalDrug CompoundingExcipientsSuspensionsTabletsTensile StrengthAcetaminophenCelluloseExcipientsSuspensionsTabletscompactionfluidized bed coatingnanocellulosetabletabilitytwin-screw

Identifiers

PMID40855380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.